Edition:
United Kingdom

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

17.45USD
4:41pm BST
Change (% chg)

$-0.20 (-1.13%)
Prev Close
$17.65
Open
$17.60
Day's High
$17.65
Day's Low
$17.40
Volume
26,839
Avg. Vol
255,251
52-wk High
$20.00
52-wk Low
$8.68

Latest Key Developments (Source: Significant Developments)

Alder Announces $250 Million Committed Equity Financing
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES $250 MILLION COMMITTED EQUITY FINANCING.ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT.ALDER BIOPHARMACEUTICALS INC - TO USE NET PROCEEDS TO FUND PAYMENTS UNDER ALDER'S EUROPEAN PATENT SETTLEMENT.ALDER BIOPHARMACEUTICALS INC - TO ALSO USE PROCEEDS FOR EPTINEZUMAB INFUSION COMMERCIALIZATION-READINESS ACTIVITIES.  Full Article

Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY.ALDER BIOPHARMACEUTICALS INC - ‍ALDER HAS AGREED TO MAKE AN IMMEDIATE ONE-TIME PAYMENT OF $25 MILLION TO TEVA​.ALDER BIOPHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALDER HAS AGREED TO WITHDRAW ITS APPEAL BEFORE EUROPEAN PATENT OFFICE.ALDER BIOPHARMACEUTICALS - UNDER TERMS CO AGREED TO PAY $75 MILLION AT EACH OF TWO SALES-RELATED MILESTONES FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER SAYS UNDER TERMS CO AGREED TO PROVIDE CERTAIN ROYALTY PAYMENTS ON NET SALES AT RATES FROM 5% TO 7% FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER - UNDER TERMS CO AGREED TO MAKE SECOND ONE-TIME PAYMENT OF $25 MILLION UPON APPROVAL OF BLA FOR EPTINEZUMAB WITH U.S. FDA.  Full Article

Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION.ALDER BIOPHARMACEUTICALS INC - ANNOUNCED THAT EPTINEZUMAB, MET PRIMARY ENDPOINT IN ITS PIVOTAL PHASE 3 PROMISE 2 CLINICAL TRIAL.ALDER BIOPHARMACEUTICALS INC - ‍15% OF PATIENTS HAD NO MIGRAINES FOR A FULL THREE MONTHS​.ALDER BIOPHARMACEUTICALS INC - IN ADDITION, EPTINEZUMAB MET ALL KEY SECONDARY ENDPOINTS WITH VERY HIGH STATISTICAL SIGNIFICANCE.ALDER BIOPHARMACEUTICALS INC - ‍SAFETY AND TOLERABILITY WERE SIMILAR TO PREVIOUSLY REPORTED EPTINEZUMAB STUDIES​.ALDER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT A BLA TO U.S. FDA FOR EPTINEZUMAB IN H2 OF 2018.  Full Article

Alder Biopharmaceuticals Q3 loss per share $0.92
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals announces third quarter 2017 financial and operating results.Q3 loss per share $0.92.Q3 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.Alder Biopharmaceuticals Inc - ‍eptinezumab biologics license application (BLA) submission on track for 2h18​.Alder Biopharmaceuticals Inc - ‍promise 2 pivotal trial completed enrollment and top-line data on track for 1h18​.Alder-Sees available cash & cash equivalents, short-term investments to be sufficient for projected requirements through late 2018/early 2019​‍​.  Full Article

Alder Biopharmaceuticals posts Q2 loss $0.79/shr
Tuesday, 26 Jul 2016 

Alder Biopharmaceuticals Inc : Alder Biopharmaceuticals reports second quarter 2016 financial and operating results . Q2 shr loss $0.79 . Q2 shr view $-0.75 -- Thomson Reuters I/B/E/S . Alder did not record any revenue in Q2 of 2015 . Net loss for Q2 ended June 30, 2016, totaled $38.9 mln, or $0.79 per share .Q2 shr view $-0.75 -- Thomson Reuters I/B/E/S.  Full Article

Allergan oral migraine drug succeeds in study

June 11 Allergan Plc said on Monday its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine.